Last-Chance brain cancer vaccine offered to select patients
NCT ID NCT04802447
Summary
This program provided expanded access to an investigational vaccine called SurVaxM for patients with glioblastoma, an aggressive brain cancer. It was for patients who had already completed a prior SurVaxM trial and wanted to continue, or for those with no access to other comparable therapies. The goal was to allow continued treatment for patients who might benefit, based on earlier trial data suggesting it could help control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.